Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials / Han ZHU ; Jia-Qi JING ; Si-Jia JIA ; Su-Hong YU ; Chang-Jiang YANG in Research in Autism Spectrum Disorders, 114 (June 2024)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 114 (June 2024) . - p.102363 Titre : Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials Type de document : Texte imprimé et/ou numérique Auteurs : Han ZHU, Auteur ; Jia-Qi JING, Auteur ; Si-Jia JIA, Auteur ; Su-Hong YU, Auteur ; Chang-Jiang YANG, Auteur Année de publication : 2024 Article en page(s) : p.102363 Langues : Anglais (eng) Mots-clés : Bumetanide  Autism spectrum disorder  Overall core symptoms  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background The efficacy of bumetanide on autism spectrum disorders (ASD) has been extensively studied, but the results remain inconclusive, necessitating a critical examination to determine its therapeutic role. Therefore, this study conducted a meta-analysis of bumetanide treatments for ASD to explore its efficacy and identify subpopulation that responded positively. Methods A systematic search was conducted on PubMed, EMBASE, MEDLINE, PsyclNFO, Web of Science, Clinical Trials.gov, and references in reviews from the earliest available date to September 2023. Randomized controlled trials (RCTs) were identified that evaluated the efficacy of bumetanide in improving overall core symptoms (OCS) of ASD. Therefore, nine studies with 1036 participants were included in the study. Results Bumetanide showed significant effects on OCS of ASD (WMD = ? 1.91, p = 0.006), particularly in sub-domains including relation to inanimate objects, adaption to environment changes, auditory response, near sensory responses, anxiety and hyperactivity. Moderating analysis indicated that a significant effect size of bumetanide on OCS of ASD was observed in specific subgroup, including 3-6 years old (WMD = ?1.08, p = 0.008), the tablet (WMD = ?2.80, p = 0.003), 3-month intervention (WMD = ?2.54, p = 0.003), and the single-center studies (WMD = ?2.80, p = 0.003). Conclusions Bumetanide has a large and significant impact on the OCS of ASD. Given the limited number and quality of included RCTs, future research should prioritize conducting large-scale trials focusing on sub-parameters or specific clinical features to comprehensively evaluate the efficacy of bumetanide in subpopulations of children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2024.102363 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=529 [article] Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials [Texte imprimé et/ou numérique] / Han ZHU, Auteur ; Jia-Qi JING, Auteur ; Si-Jia JIA, Auteur ; Su-Hong YU, Auteur ; Chang-Jiang YANG, Auteur . - 2024 . - p.102363. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 114 (June 2024) . - p.102363 Mots-clés : Bumetanide  Autism spectrum disorder  Overall core symptoms  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background The efficacy of bumetanide on autism spectrum disorders (ASD) has been extensively studied, but the results remain inconclusive, necessitating a critical examination to determine its therapeutic role. Therefore, this study conducted a meta-analysis of bumetanide treatments for ASD to explore its efficacy and identify subpopulation that responded positively. Methods A systematic search was conducted on PubMed, EMBASE, MEDLINE, PsyclNFO, Web of Science, Clinical Trials.gov, and references in reviews from the earliest available date to September 2023. Randomized controlled trials (RCTs) were identified that evaluated the efficacy of bumetanide in improving overall core symptoms (OCS) of ASD. Therefore, nine studies with 1036 participants were included in the study. Results Bumetanide showed significant effects on OCS of ASD (WMD = ? 1.91, p = 0.006), particularly in sub-domains including relation to inanimate objects, adaption to environment changes, auditory response, near sensory responses, anxiety and hyperactivity. Moderating analysis indicated that a significant effect size of bumetanide on OCS of ASD was observed in specific subgroup, including 3-6 years old (WMD = ?1.08, p = 0.008), the tablet (WMD = ?2.80, p = 0.003), 3-month intervention (WMD = ?2.54, p = 0.003), and the single-center studies (WMD = ?2.80, p = 0.003). Conclusions Bumetanide has a large and significant impact on the OCS of ASD. Given the limited number and quality of included RCTs, future research should prioritize conducting large-scale trials focusing on sub-parameters or specific clinical features to comprehensively evaluate the efficacy of bumetanide in subpopulations of children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2024.102363 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=529

A Review on Autism Spectrum Disorder Screening by Artificial Intelligence Methods / Si-Jia JIA in Journal of Autism and Developmental Disorders, 55-9 (September 2025)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 55-9 (September 2025) . - p.3011-3027 Titre : A Review on Autism Spectrum Disorder Screening by Artificial Intelligence Methods Type de document : Texte imprimé et/ou numérique Auteurs : Si-Jia JIA, Auteur ; Jia-Qi JING, Auteur ; Chang-Jiang YANG, Auteur Article en page(s) : p.3011-3027 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : With the increasing prevalence of autism spectrum disorders (ASD), the importance of early screening and diagnosis has been subject to considerable discussion. Given the subtle differences between ASD children and typically developing children during the early stages of development, it is imperative to investigate the utilization of automatic recognition methods powered by artificial intelligence. We aim to summarize the research work on this topic and sort out the markers that can be used for identification. En ligne : https://doi.org/10.1007/s10803-024-06429-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=566 [article] A Review on Autism Spectrum Disorder Screening by Artificial Intelligence Methods [Texte imprimé et/ou numérique] / Si-Jia JIA, Auteur ; Jia-Qi JING, Auteur ; Chang-Jiang YANG, Auteur . - p.3011-3027. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 55-9 (September 2025) . - p.3011-3027 Index. décimale : PER Périodiques Résumé : With the increasing prevalence of autism spectrum disorders (ASD), the importance of early screening and diagnosis has been subject to considerable discussion. Given the subtle differences between ASD children and typically developing children during the early stages of development, it is imperative to investigate the utilization of automatic recognition methods powered by artificial intelligence. We aim to summarize the research work on this topic and sort out the markers that can be used for identification. En ligne : https://doi.org/10.1007/s10803-024-06429-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=566

The effect of omega-3 fatty acid supplementation on autism spectrum disorder: A meta-analysis / Jia-Qi JING ; Li-Xin YI ; Chang-Jiang YANG in Research in Autism, 126 (August 2025)  

Public ISBD [article]  inResearch in Autism > 126 (August 2025) . - p.202642 Titre : The effect of omega-3 fatty acid supplementation on autism spectrum disorder: A meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : Jia-Qi JING, Auteur ; Li-Xin YI, Auteur ; Chang-Jiang YANG, Auteur Article en page(s) : p.202642 Langues : Anglais (eng) Mots-clés : Omega-3 fatty acid  ASD  Meta-analysis Index. décimale : PER Périodiques Résumé : Background Omega-3 therapy for ASD is often used as a complementary and alternative medical approach, however, its impact on the core symptoms of ASD is controversial. Therefore, accurately determining the role of Omega-3 in ASD can establish a foundation for parents and doctors to formulate treatment plans. The current study aimed to include randomized controlled trials and provide a meta-analysis to evaluate the impact of Omega-3 fatty acids on the core symptoms of ASD. Method We searched the papers published in the Web of Science, PubMed, Medline, Scopus, EBSCO, SpringerLink, and Wiley Online Library databases until 10th April 2024 with 11 articles included. The meta-analysis evaluated the overall effects of Omega-3 fatty acids on core ASD behaviors and the effects on hyperactivity behavior, stereotype behavior, communication difficulty, and emotional difficulty. Results Results indicated that, compared to placebo, the Omega-3 fatty acids had a small and non-significant effect on the overall behavior [SMD= ?0.1, 95 % CI (?0.36,0.17), p = 0.47], with the same effect on hyperactivity behavior [SMD= ?0.24, 95 % CI (?0.55,0.08), p = 0.14], stereotyped behavior [SMD= ?0.2, 95 % CI (?0.47,0.07), p = 0.15], communication difficulty [SMD= ?0.09, 95 % CI (?0.42,0.24), p = 0.60], and emotional difficulty [SMD= ?0.15, 95 % CI (?0.45,0.14), p = 0.3]. Conclusions Overall, Omega-3 fatty acids have a minor and insignificant effect on ASD behaviors, which may be related to treatment protocol and appropriateness of participants. In the future, more large-scale and rigorous randomized controlled trials are needed to further obtain more convincing conclusions. En ligne : https://doi.org/10.1016/j.reia.2025.202642 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=565 [article] The effect of omega-3 fatty acid supplementation on autism spectrum disorder: A meta-analysis [Texte imprimé et/ou numérique] / Jia-Qi JING, Auteur ; Li-Xin YI, Auteur ; Chang-Jiang YANG, Auteur . - p.202642. Langues : Anglais (eng) in Research in Autism > 126 (August 2025) . - p.202642 Mots-clés : Omega-3 fatty acid  ASD  Meta-analysis Index. décimale : PER Périodiques Résumé : Background Omega-3 therapy for ASD is often used as a complementary and alternative medical approach, however, its impact on the core symptoms of ASD is controversial. Therefore, accurately determining the role of Omega-3 in ASD can establish a foundation for parents and doctors to formulate treatment plans. The current study aimed to include randomized controlled trials and provide a meta-analysis to evaluate the impact of Omega-3 fatty acids on the core symptoms of ASD. Method We searched the papers published in the Web of Science, PubMed, Medline, Scopus, EBSCO, SpringerLink, and Wiley Online Library databases until 10th April 2024 with 11 articles included. The meta-analysis evaluated the overall effects of Omega-3 fatty acids on core ASD behaviors and the effects on hyperactivity behavior, stereotype behavior, communication difficulty, and emotional difficulty. Results Results indicated that, compared to placebo, the Omega-3 fatty acids had a small and non-significant effect on the overall behavior [SMD= ?0.1, 95 % CI (?0.36,0.17), p = 0.47], with the same effect on hyperactivity behavior [SMD= ?0.24, 95 % CI (?0.55,0.08), p = 0.14], stereotyped behavior [SMD= ?0.2, 95 % CI (?0.47,0.07), p = 0.15], communication difficulty [SMD= ?0.09, 95 % CI (?0.42,0.24), p = 0.60], and emotional difficulty [SMD= ?0.15, 95 % CI (?0.45,0.14), p = 0.3]. Conclusions Overall, Omega-3 fatty acids have a minor and insignificant effect on ASD behaviors, which may be related to treatment protocol and appropriateness of participants. In the future, more large-scale and rigorous randomized controlled trials are needed to further obtain more convincing conclusions. En ligne : https://doi.org/10.1016/j.reia.2025.202642 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=565

---

1 (1 - 3 / 3)